High frequency of mutations in gyrA gene associated with quinolones resistance in uropathogenic Escherichia coli isolates from the north of Iran

Document Type : Original Article


1 Department of Microbiology, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran

2 Department of Biostatistics, Faculty of Medicine, Guilan University of Medical Sciences, Rasht- Iran


Objective(s): Regarding the global burden of uropathogenic Escherichia coli (UPEC) infections, prevention and treatment of such infections play a significant role in healthcare management. The inordinate use of fluoroquinolones led to a worldwide spread of quinolone-resistant strains. Therefore, this study aimed to investigate mutations in codons 83 and 106 of gyrA gene in UPEC isolates in the north of Iran.
Materials and Methods: This cross-sectional study performed on a total of 223 UPEC isolates which were recovered within 6 months in 2017. Isolates were identified and confirmed by standard microbiologic tests, and antimicrobial susceptibility testing was carried out by disk diffusion and E-test methods. PCR reaction was performed to amplify gyrA gene, and PCR-RFLP was performed using BsiEI and BstU‌I restriction enzymes to investigate mutations in gyrA gene.
Results: The nalidixic acid, ciprofloxacin, ofloxacin, and norfloxacin resistance rates were 61.9%, 50.2%, 48.25, and 45.3%, respectively. Overall, 55.2% of E. coli isolates had a mutation in gyrA gene in codon 83, and 20.2% in codon 106. Also, 15.2% of isolates had simultaneously mutation. Moreover, a significant association was found between mutations in gyrA gene and quinolone and fluoroquinolones resistance pattern of UPEC isolates.
Conclusion: Our results revealed a high level of quinolone resistance associated with the mutations in gyrA among the clinical isolates of UPEC in our region. To the best of our knowledge, this study is the first investigation on the role of gyrA alteration in quinolone resistance among UPEC isolates from the north of Iran.


Main Subjects

1. Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry 2014; 53:1565-1574.
2. Anvarinejad M, Farshad S, Alborzi A, Ranjbar R, Giammanco GM, Japoni A. Integron and genotype patterns of quinolones-resistant uropathogenic Escherichia coli. Afr J Microbiol Res 2011; 5:3736-3770.
3. Ito CA, Gales AC, Tognim MC, Munerato P, Dalla Costa LM. Quinolone-resistant Escherichia coli. Braz J Infect Dis 2008; 12:5-9.
4. Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47:3222-3232.
5. Pourahmad Jaktaji R, Mohiti E. Study of Mutations in the DNA gyrase gyrA Gene of Escherichia coli. Iran J Pharm Res 2010; 9:43-48.
6. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem 2014; 6:25-64.
7. Ghaffarian F, Hedayati M, Sedigh Ebrahim-Saraie H, Atrkar Roushan Z, Mojtahedi A. Molecular epidemiology of ESBL-producing Klebsiella pneumoniae isolates in intensive care units of a tertiary care hospital, North of Iran. Cell Mol Biol (Noisy-le-grand) 2018; 64:75-79.
8. Soltani B, Heidari H, Ebrahim-Saraie HS, Hadi N, Mardaneh J, Motamedifar M. Molecular characteristics of multiple and extensive drug-resistant Acinetobacter baumannii isolates obtained from hospitalized patients in Southwestern Iran. Infez Med 2018; 26:67-76.
9. Haghighatpanah M, Mozaffari Nejad AS, Mojtahedi A, Amirmozafari N, Zeighami H. Detection of extended-spectrum beta-lactamase (ESBL) and plasmid-borne blaCTX-M and blaTEM genes among clinical strains of Escherichia coli isolated from patients in the north of Iran. J Glob Antimicrob Resist 2016; 7:110-113.
10. Vila J, Ruiz J, Marco F, Barcelo A, Goni P, Giralt E, et al. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother 1994; 38:2477-2479.
11. Friedman SM, Lu T, Drlica K. Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob Agents Chemother 2001; 45:2378-2380.
12. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61:377-392.
13. Ruiz J, Gomez J, Navia MM, Ribera A, Sierra JM, Marco F, et al. High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagn Microbiol Infect Dis 2002; 42:257-261.
14. Johnning A, Kristiansson E, Fick J, Weijdegard B, Larsson DG. Resistance mutations in gyra and parc are common in escherichia communities of both fluoroquinolone-polluted and uncontaminated aquatic environments. Front Microbiol 2015; 6:1355.
15. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003; 51:1109-1117.
16. Cockerill FR, 3rd. Genetic methods for assessing antimicrobial resistance. Antimicrob Agents Chemother 1999; 43:199-212.
17. Wayne PA. Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute (CLSI supplement M100) 2017; 27th ed.
18. Bien J, Sokolova O, Bozko P. Role of uropathogenic Escherichia coli virulence factors in development of urinary tract infection and kidney damage. Int J Nephrol 2012; 2012:681473-681487.
19. Dalhoff A. Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis 2012; 2012:976273.
20. Rezaee MA, Abdinia B. Etiology and antimicrobial susceptibility pattern of pathogenic bacteria in children subjected to uti: a referral hospital-based study in Northwest of Iran. Medicine (Baltimore) 2015; 94:e1606.
21. Sedighi I, Arabestani MR, Rahimbakhsh A, Karimitabar Z, Alikhani MY. Dissemination of extended-spectrum beta-lactamases and quinolone resistance genes among clinical isolates of uropathogenic Escherichia coli in children. Jundishapur J Microbiol 2015; 8:e19184.
22. Momtaz H, Karimian A, Madani M, Safarpoor Dehkordi F, Ranjbar R, Sarshar M, et al. Uropathogenic Escherichia coli in Iran: serogroup distributions, virulence factors and antimicrobial resistance properties. Ann Clin Microbiol Antimicrob 2013; 12:8.
23. Neamati F, Firoozeh F, Saffari M, Zibaei M. Virulence genes and antimicrobial resistance pattern in uropathogenic Escherichia coli Isolated from hospitalized patients in Kashan, Iran. Jundishapur J Microbiol 2015; 8:e17514.
24. Dehbanipour R, Rastaghi S, Sedighi M, Maleki N, Faghri J. High prevalence of multidrug-resistance uropathogenic Escherichia coli strains, Isfahan, Iran. J Nat Sci Biol Med 2016; 7:22-26.
25. Ranjbar R, Farahani O. The Prevalence of plasmid-mediated quinolone resistance genes in Escherichia coli isolated from hospital wastewater sources in Tehran, Iran. Iran J Public Health 2017; 46:1285-1291.
26. Ebrahim-Saraie HS, Nezhad NZ, Heidari H, Motamedifar A, Motamedifar M. Detection of antimicrobial susceptibility and integrons among extended-spectrum beta-lactamase producing uropathogenic Escherichia coli isolates in Southwestern Iran. Oman Med J 2018; 33:218-223.
27. Shariff VAA, Shenoy MS, Yadav T, M R. The antibiotic susceptibility patterns of uropathogenic Escherichia coli, with special reference to the fluoroquinolones. J Clin Diagn Res 2013; 7:1027-1030.
28. Basu S, Mukherjee SK, Hazra A, Mukherjee M. Molecular characterization of uropathogenic Escherichia coli: nalidixic acid and ciprofloxacin resistance, virulent factors and phylogenetic background. J Clin Diagn Res 2013; 7:2727-2731.
29. Moreira da Silva RCR, de Oliveira Martins Junior P, Goncalves LF, de Paulo Martins V, de Melo ABF, Pitondo-Silva A, et al. Ciprofloxacin resistance in uropathogenic Escherichia coli isolates causing community-acquired urinary infections in Brasilia, Brazil. J Glob Antimicrob Resist 2017; 9:61-67.
30. Olorunmola FO, Kolawole DO, Lamikanra A. Antibiotic resistance and virulence properties in Escherichia coli strains from cases of urinary tract infections. Afr J Infect Dis 2013; 7:1-7.
31. Piatti G, Mannini A, Balistreri M, Schito AM. Virulence factors in urinary Escherichia coli strains: phylogenetic background and quinolone and fluoroquinolone resistance. J Clin Microbiol 2008; 46:480-487.
32. Wang Y, Zhao S, Han L, Guo X, Chen M, Ni Y, et al. Drug resistance and virulence of uropathogenic Escherichia coli from Shanghai, China. J Antibiot (Tokyo) 2014; 67:799-805.
33. Lavigne JP, Bruyere F, Bernard L, Combescure C, Ronco E, Lanotte P, et al. Resistance and virulence potential of uropathogenic Escherichia coli strains isolated from patients hospitalized in urology departments: a French prospective multicentre study. J Med Microbiol 2016; 65:530-537.
34. Ardebili A, Lari AR, Beheshti M, Lari ER. Association between mutations in gyrA and parC genes of Acinetobacter baumannii clinical isolates and ciprofloxacin resistance. Iran J Basic Med Sci 2015; 18:623-626.
35. Liu BT, Liao XP, Yang SS, Wang XM, Li LL, Sun J, et al. Detection of mutations in the gyrA and parC genes in Escherichia coli isolates carrying plasmid-mediated quinolone resistance genes from diseased food-producing animals. J Med Microbiol 2012; 61:1591-1599.
36. Minarini LA, Darini AL. Mutations in the quinolone resistance-determining regions of gyrA and parC in Enterobacteriaceae isolates from Brazil. Braz J Microbiol 2012; 43:1309-1314.
37. Namboodiri SS, Opintan JA, Lijek RS, Newman MJ, Okeke IN. Quinolone resistance in Escherichia coli from Accra, Ghana. BMC Microbiol 2011; 11:44.
38. Nouri R, Ahangarzadeh Rezaee M, Hasani A, Aghazadeh M, Asgharzadeh M. The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran. Braz J Microbiol 2016; 47:925-930.
39. Wang Y-T, Lee M-F, Peng C-F. Mutations in the quinolone resistance-determining regions associated with ciprofloxacin resistance in Pseudomonas aeruginosa isolates from Southern Taiwan. Biomarkers Genom Med 2014; 6:79-83.
40. Abbasi H, Ranjbar R. The prevalence of quinolone resistance genes of A, B, S in Escherichia coli strains isolated from three major hospitals in Tehran, Iran. Cent European J Urol 2018; 71:129-133.